These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26033247)

  • 1. Xenograft models for adrenocortical carcinoma.
    Hantel C; Beuschlein F
    Mol Cell Endocrinol; 2016 Feb; 421():28-33. PubMed ID: 26033247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse models of adrenal tumorigenesis.
    Hantel C; Beuschlein F
    Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):865-75. PubMed ID: 21115155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in understanding the molecular underpinnings of adrenocortical tumors.
    Nicolson NG; Man J; Carling T
    Curr Opin Oncol; 2018 Jan; 30(1):16-22. PubMed ID: 29028646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of a human adrenocortical carcinoma xenograft model.
    Logié A; Boudou P; Boccon-Gibod L; Baudin E; Vassal G; Schlumberger M; Le Bouc Y; Gicquel C
    Endocrinology; 2000 Sep; 141(9):3165-71. PubMed ID: 10965887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular markers and the pathogenesis of adrenocortical cancer.
    Soon PS; McDonald KL; Robinson BG; Sidhu SB
    Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenocortical carcinoma: review and update.
    Erickson LA; Rivera M; Zhang J
    Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of new preclinical models to advance adrenocortical carcinoma research.
    Kiseljak-Vassiliades K; Zhang Y; Bagby SM; Kar A; Pozdeyev N; Xu M; Gowan K; Sharma V; Raeburn CD; Albuja-Cruz M; Jones KL; Fishbein L; Schweppe RE; Somerset H; Pitts TM; Leong S; Wierman ME
    Endocr Relat Cancer; 2018 Apr; 25(4):437-451. PubMed ID: 29371329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
    Pinto EM; Morton C; Rodriguez-Galindo C; McGregor L; Davidoff AM; Mercer K; Debelenko LV; Billups C; Ribeiro RC; Zambetti GP
    Clin Cancer Res; 2013 Apr; 19(7):1740-7. PubMed ID: 23406775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
    Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
    Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.
    Beuschlein F; Jakoby J; Mentz S; Zambetti G; Jung S; Reincke M; Süss R; Hantel C
    Mol Cell Endocrinol; 2016 Jun; 428():82-8. PubMed ID: 26994514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next step: mechanisms driving adrenocortical carcinoma metastasis.
    Lalli E; Luconi M
    Endocr Relat Cancer; 2018 Feb; 25(2):R31-R48. PubMed ID: 29142005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on in-vivo preclinical research models in adrenocortical carcinoma.
    Kar A; Wierman ME; Kiseljak-Vassiliades K
    Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):170-176. PubMed ID: 32304391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
    Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
    J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Assessment of
    Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
    Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
    Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.